Who are SynOx Therapeutics Ltd's investors?

SynOx Therapeutics Ltd's investors include HealthCap, Bioqube Ventures, Forbion, Gimv, Medicxi, Red Tree Venture.

SynOx Therapeutics Ltd

Founded 2020 · 33 employees on LinkedIn · 6 known investors

Find your way into SynOx Therapeutics Ltd

Paths you didn't know you had: your email and LinkedIn already hold routes to the SynOx Therapeutics Ltd team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

SynOx Therapeutics develops emactuzumab, a monoclonal antibody treatment for tenosynovial giant cell tumours (TGCT) and macrophage-mediated diseases. The company focuses on bringing a differentiated drug candidate through clinical development and commercialisation to address unmet patient needs in rare and debilitating diseases.

Biotech Healthtech Medical Devices

Founders & leadership

Ray Barlow Chief Executive OfficerRay Barlow served as CBO of Kiadis Pharma, where he negotiated a licensing agreement with Sanofi preceding the company's acquisition, and as CEO of e-Therapeutics PLC leading a business turnaround. His earlier experience includes roles at Amgen as Executive Director of corporate development, Senior Director at Crucell before its 2011 acquisition by Johnson & Johnson for $2.3 billion, and positions in business development and commercial strategy at AstraZeneca.

Investors · 6

HealthCap✓ confirmed by SynOx Therapeutics LtdStockholm

How we know: the company's own site · HealthCap's portfolio page · funding news · prnewswire.com · Not right? Tell us

Bioqube Ventures✓ confirmed by SynOx Therapeutics LtdBrussels · $108K – $6.5M

How we know: the company's own site · open dataset · 5k.vc investor directory · Not right? Tell us

Forbion✓ confirmed by SynOx Therapeutics LtdNaarden

How we know: the company's own site · a partner's Signal profile · funding news · prnewswire.com · open dataset · 5k.vc investor directory · Not right? Tell us

GimvreportedAntwerp · $20M – $400M

How we know: funding news · prnewswire.com · Not right? Tell us

MedicxireportedLondon

How we know: funding news · prnewswire.com · Not right? Tell us

Red Tree VenturereportedSan Diego

How we know: a partner's Signal profile · Not right? Tell us

Funding

SEC filings, press & company announcements

Undisclosed amountSeries ANov 2020
HealthCap (lead), Medicxi (lead), Forbion, Gimv
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

In the news

SynOx Therapeutics | EU-Startupseu-startups.com · Jun 2022

SynOx Therapeutics raises €37M in Series A Financingprnewswire.com · Nov 2020

Frequently asked questions

What does SynOx Therapeutics Ltd do?: SynOx Therapeutics develops emactuzumab, a monoclonal antibody treatment for tenosynovial giant cell tumours (TGCT) and macrophage-mediated diseases. The company focuses on bringing a differentiated drug candidate through clinical development and commercialisation to address unmet patient needs in rare and debilitating diseases.
Who are SynOx Therapeutics Ltd's investors?: SynOx Therapeutics Ltd's investors include HealthCap, Bioqube Ventures, Forbion, Gimv, Medicxi, Red Tree Venture.